{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,9]],"date-time":"2026-09-09T09:09:40Z","timestamp":1788944980585,"version":"build-2803163510"},"reference-count":20,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2026,7,16]],"date-time":"2026-07-16T00:00:00Z","timestamp":1784160000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/deed.de"},{"start":{"date-parts":[[2026,7,16]],"date-time":"2026-07-16T00:00:00Z","timestamp":1784160000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/deed.de"}],"funder":[{"name":"Deutsches Rheuma-Forschungszentrum Berlin (DRFZ)"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Z Rheumatol"],"published-print":{"date-parts":[[2026,9]]},"abstract":"<jats:title>Zusammenfassung<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Hintergrund<\/jats:title>\n                    <jats:p>Die Versorgung \u00e4lterer Menschen mit entz\u00fcndlich-rheumatischen Erkrankungen (ERE) gewinnt immer mehr an Bedeutung. Im Jahresbericht 2026 aus der Kerndokumentation werden Charakteristika von Patienten mit ERE im h\u00f6heren Lebensalter sowie Entwicklungen in der medikament\u00f6sen Therapie dargestellt.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methodik<\/jats:title>\n                    <jats:p>Patienten aus der ambulanten rheumatologischen Routineversorgung und ihre behandelnden Rheumatologen dokumentieren einmal j\u00e4hrlich Krankheitsverlauf, Therapien und Krankheitsfolgen. Es wurden Daten von 2010 bis 2024 ber\u00fccksichtigt und nach Altersgruppen ausgewertet.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Ergebnisse<\/jats:title>\n                    <jats:p>Im Jahr 2024 wurden 13.416 Patienten aus 14 rheumatologischen Einrichtungen eingeschlossen, 52\u202f% waren \u2265\u202f60\u00a0Jahre alt. Die h\u00e4ufigsten ERE ab 60\u00a0Jahren waren rheumatoide Arthritis (RA 57\u202f%), Psoriasis-Arthritis (PsA 12\u202f%), axiale Spondyloarthritis (axSpA 7\u202f%), Polymyalgia rheumatica (PMR 6\u202f%) und Riesenzellarteriitis (RZA 5\u202f%). Die mittlere Zahl an Komorbidit\u00e4ten stieg mit zunehmendem Alter von 1,3 (18\u201339\u00a0Jahre) bis 4,4 (\u2265\u202f80\u00a0Jahre). Insbesondere Frauen hatten mit zunehmendem Alter mehr Funktionseinschr\u00e4nkungen und Schmerzen. \u00c4ltere Menschen erhielten h\u00e4ufiger Glukokortikoide und Analgetika, aber seltener Biologika als j\u00fcngere. Bei RA erhielten Patienten \u2265\u202f80\u00a0Jahre im Vergleich zu 18- bis 39-j\u00e4hrigen Patienten z.\u202fB. 25\u202f% (\u2265\u202f80) vs.\u00a047\u202f% [18\u201339] Biologika und 37\u202f% vs.\u00a013\u202f% Glukokortikoide. Dennoch folgen die Ver\u00e4nderungen dem Gesamttrend. So ist der Einsatz von biologischen krankheitsmodifizierenden Antirheumatika (bDMARDs) seit 2010 bei den \u2265\u202f80-j\u00e4hrigen RA-Patienten von 7 auf 25\u202f% gestiegen, w\u00e4hrend Glukokortikoide von 63\u202f% auf 37\u202f% zur\u00fcckgingen.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Schlussfolgerung<\/jats:title>\n                    <jats:p>Trotz der insgesamt noch immer deutlich niedrigeren Rate an Biologika-Therapie im h\u00f6heren Lebensalter zeigen die Langzeitdaten der Kerndokumentation, dass Biologika auch bei \u00e4lteren Patienten im Vergleich zu vorherigen Kalenderjahren h\u00e4ufiger verordnet werden.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1007\/s00393-026-01847-9","type":"journal-article","created":{"date-parts":[[2026,7,16]],"date-time":"2026-07-16T05:23:45Z","timestamp":1784179425000},"page":"578-587","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Rheumatologische Versorgung \u00e4lterer Menschen","Rheumatological care of older people"],"prefix":"10.1007","volume":"85","author":[{"given":"Katinka","family":"Albrecht","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katja","family":"Thiele","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tobias","family":"Alexander","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin","family":"Aringer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jacqueline","family":"Detert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thorsten","family":"Eidner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin","family":"Feuchtenberger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J\u00f6rg","family":"Henes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kirsten","family":"Karberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Uta","family":"Kiltz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benjamin","family":"K\u00f6hler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Udo","family":"Schneider","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jutta G.","family":"Richter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guido","family":"Sch\u00e4fer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susanna","family":"Sp\u00e4thling-Mestekemper","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mirko","family":"Steinm\u00fcller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Silke","family":"Zinke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anja","family":"Strangfeld","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Johanna","family":"Callhoff","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,7,16]]},"reference":[{"key":"1847_CR1","unstructured":"Bundesinstitut f\u00fcr Bev\u00f6lkerungsforschung (BiB) (2024) Anteile der Altersgruppen unter 20 Jahren, ab 65 Jahre und ab 80 Jahre (1871-2070). https:\/\/www.bib.bund.de\/DE\/Fakten\/Fakt\/B15-Altersgruppen-Bevoelkerung-1871-Vorausberechnung.html?nn=116880. Zugegriffen: 7. Jan. 2026"},{"issue":"Suppl 2","key":"1847_CR2","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1007\/s00393-024-01539-2","volume":"83","author":"J Braun","year":"2024","unstructured":"Braun\u00a0J, Albrecht\u00a0K, Callhoff\u00a0J, Haase\u00a0I, Krause\u00a0A, Lakomek\u00a0HJ, Meyer-Olson\u00a0D, Schmale-Grede\u00a0R, Wagner\u00a0U, Zeidler\u00a0J, Zinke\u00a0S, Voormann\u00a0A, Specker\u00a0C, die Kommission Versorgung der D (2024) Rheumatologische Versorgung in Deutschland : Memorandum der Deutschen Gesellschaft f\u00fcr Rheumatologie und Klinische Immunologie 2024. Z Rheumatol 83(Suppl 2):249\u2013284. https:\/\/doi.org\/10.1007\/s00393-024-01539-2","journal-title":"Z Rheumatol"},{"key":"1847_CR3","doi-asserted-by":"publisher","DOI":"10.1136\/rmdopen-2024-005383","author":"K Tang","year":"2025","unstructured":"Tang\u00a0K, Zhu\u00a0L, Shan\u00a0S, Luo\u00a0Z, Zhou\u00a0J, Ying\u00a0J, Wu\u00a0J, Shen\u00a0G, Song\u00a0P (2025) Global, regional and national trends in the epidemiology of rheumatoid arthritis from 1990 to 2021: an age-period-cohort effect analysis of the global burden of disease study 2021. RMD Open. https:\/\/doi.org\/10.1136\/rmdopen-2024-005383","journal-title":"RMD Open"},{"issue":"3","key":"1847_CR4","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1007\/s00393-013-1242-6","volume":"73","author":"C Fiehn","year":"2014","unstructured":"Fiehn\u00a0C (2014) Welche Versorgungsstrukturen werden fur \u00e4ltere Patienten mit rheumatischen Erkrankungen ben\u00f6tigt? Z Rheumatol 73(3):217\u2013224. https:\/\/doi.org\/10.1007\/s00393-013-1242-6","journal-title":"Z Rheumatol"},{"key":"1847_CR5","doi-asserted-by":"crossref","unstructured":"Strangfeld A, Zink A (2024) Sicherheit und Wirksamkeit der Therapie der rheumatoiden Arthritis im Alter: Was sagen Register- und Routinedaten? Akt Rheumatol 2024; 49(05): 301-309 DOI: 101055\/a-2347-9759","DOI":"10.1055\/a-2347-9759"},{"issue":"10","key":"1847_CR6","doi-asserted-by":"publisher","first-page":"2199","DOI":"10.1002\/acr.25116","volume":"75","author":"A Dolomisiewicz","year":"2023","unstructured":"Dolomisiewicz\u00a0A, Ali\u00a0H, Roul\u00a0P, Yang\u00a0Y, Cannon\u00a0GW, Sauer\u00a0B, Baker\u00a0JF, Mikuls\u00a0TR, Michaud\u00a0K, England\u00a0BR (2023) Updating and Validating the Rheumatic Disease Comorbidity Index to Incorporate ICD-10-CM Diagnostic Codes. Arthritis Care Res 75(10):2199\u20132206. https:\/\/doi.org\/10.1002\/acr.25116","journal-title":"Arthritis Care Res (Hoboken)"},{"issue":"3","key":"1847_CR7","doi-asserted-by":"publisher","first-page":"144","DOI":"10.1007\/s003930050030","volume":"56","author":"J Lautenschl\u00e4ger","year":"1997","unstructured":"Lautenschl\u00e4ger\u00a0J, Mau\u00a0W, Kohlmann\u00a0T, Raspe\u00a0HH, Struve\u00a0F, Bruckle\u00a0W, Zeidler\u00a0H (1997) Vergleichende Evaluation einer deutschen Version des Health Assessment Questionnaires (HAQ) und des Funktionsfragebogens Hannover (FFbH). Z Rheumatol 56(3):144\u2013155. https:\/\/doi.org\/10.1007\/s003930050030","journal-title":"Z Rheumatol"},{"issue":"12","key":"1847_CR8","first-page":"2286","volume":"21","author":"S Garrett","year":"1994","unstructured":"Garrett\u00a0S, Jenkinson\u00a0T, Kennedy\u00a0LG, Whitelock\u00a0H, Gaisford\u00a0P, Calin\u00a0A (1994) A new approach to defining disease status in ankylosing spondylitis: the Bath Ankylosing Spondylitis Disease Activity Index. J\u00a0Rheumatol 21(12):2286\u20132291","journal-title":"J Rheumatol"},{"key":"1847_CR9","unstructured":"European Medicines Agency (2023) EMA confirms measures to minimise risk of serious side effects with Janus kinase inhibitors for chronic inflammatory disorders (EMA\/27681\/2023). https:\/\/www.ema.europa.eu\/en\/medicines\/human\/referrals\/janus-kinase-inhibitors-jaki. Zugegriffen: 31. M\u00e4rz 2026"},{"issue":"6","key":"1847_CR10","doi-asserted-by":"publisher","DOI":"10.1016\/j.autrev.2020.102528","volume":"19","author":"L Serhal","year":"2020","unstructured":"Serhal\u00a0L, Lwin\u00a0MN, Holroyd\u00a0C, Edwards\u00a0CJ (2020) Rheumatoid arthritis in the elderly: Characteristics and treatment considerations. Autoimmun Rev 19(6):102528. https:\/\/doi.org\/10.1016\/j.autrev.2020.102528","journal-title":"Autoimmun Rev"},{"issue":"3","key":"1847_CR11","doi-asserted-by":"publisher","first-page":"243","DOI":"10.1007\/s00393-021-00962-z","volume":"80","author":"K Albrecht","year":"2021","unstructured":"Albrecht\u00a0K, Marschall\u00a0U, Callhoff\u00a0J (2021) Verordnung von Schmerzmitteln bei Patienten mit rheumatischen Erkrankungen in Deutschland : Eine Analyse von Abrechnungsdaten. Z Rheumatol 80(3):243\u2013250. https:\/\/doi.org\/10.1007\/s00393-021-00962-z","journal-title":"Z Rheumatol"},{"issue":"2","key":"1847_CR12","doi-asserted-by":"publisher","first-page":"116","DOI":"10.1111\/bcpt.13310","volume":"126","author":"F Hoffmann","year":"2020","unstructured":"Hoffmann\u00a0F, Bantel\u00a0C, Jobski\u00a0K (2020) Agranulocytosis attributed to metamizole: An analysis of spontaneous reports in EudraVigilance 1985-2017. Basic Clin Pharmacol Toxicol 126(2):116\u2013125. https:\/\/doi.org\/10.1111\/bcpt.13310","journal-title":"Basic Clin Pharmacol Toxicol"},{"issue":"2","key":"1847_CR13","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1007\/s00393-022-01308-z","volume":"82","author":"C Fiehn","year":"2023","unstructured":"Fiehn\u00a0C, Leipe\u00a0J, Weseloh\u00a0C, Bergner\u00a0R, Kr\u00fcger\u00a0K (2023) Bewertung von Wechselwirkungen und Dosierungsempfehlungen von synthetischen DMARDs - Evidenz- und konsensbasierte Empfehlungen auf Basis einer systematischen Literatursuche. Z Rheumatol 82(2):151\u2013162. https:\/\/doi.org\/10.1007\/s00393-022-01308-z","journal-title":"Z Rheumatol"},{"key":"1847_CR14","unstructured":"Deutsche Schmerzgesellschaft e.\u202fV. DGfGeV, UVSD SchmerzLOS e.\u202fV. (Hrsg) (2025) S3-Leitlinie Schmerzmanagement bei Geriatrischen Patient:innen in allen Versorgungssettings (GeriPAIN). Kurzfassung 1.0, 2025, AWMF-Registernummer 145\/005. https:\/\/register.awmf.org\/de\/leitlinien\/detail\/145-005. Zugegriffen: 26. M\u00e4rz 206"},{"issue":"5","key":"1847_CR15","doi-asserted-by":"publisher","first-page":"369","DOI":"10.1007\/s00393-022-01181-w","volume":"81","author":"P Klemm","year":"2022","unstructured":"Klemm\u00a0P, M\u00fcller-Ladner\u00a0U, Lange\u00a0U (2022) Multimodale rheumatologische Komplexbehandlung : Eine aktuelle Bestandsaufnahme. Z Rheumatol 81(5):369\u2013375. https:\/\/doi.org\/10.1007\/s00393-022-01181-w","journal-title":"Z Rheumatol"},{"issue":"9","key":"1847_CR16","doi-asserted-by":"publisher","first-page":"727","DOI":"10.1007\/s00393-022-01305-2","volume":"82","author":"K Albrecht","year":"2023","unstructured":"Albrecht\u00a0K, Binder\u00a0S, Minden\u00a0K, Poddubnyy\u00a0D, Regierer\u00a0AC, Strangfeld\u00a0A, Callhoff\u00a0J (2023) Systematisches Review zur Sch\u00e4tzung der Pr\u00e4valenz entz\u00fcndlich-rheumatischer Erkrankungen in Deutschland. Z Rheumatol 82(9):727\u2013738. https:\/\/doi.org\/10.1007\/s00393-022-01305-2","journal-title":"Z Rheumatol"},{"issue":"2","key":"1847_CR17","doi-asserted-by":"publisher","first-page":"102","DOI":"10.1007\/s00393-017-0294-4","volume":"77","author":"K Albrecht","year":"2018","unstructured":"Albrecht\u00a0K, Luque Ramos\u00a0A, Callhoff\u00a0J, Hoffmann\u00a0F, Minden\u00a0K, Zink\u00a0A (2018) Ambulante Versorgung und Krankheitslast der rheumatoiden Arthritis : Eine Analyse von Abrechnungsdaten und einer Versichertenbefragung. Z Rheumatol 77(2):102\u2013112. https:\/\/doi.org\/10.1007\/s00393-017-0294-4","journal-title":"Z Rheumatol"},{"issue":"9","key":"1847_CR18","doi-asserted-by":"publisher","first-page":"865","DOI":"10.1007\/s00393-019-0650-7","volume":"78","author":"H Haibel","year":"2019","unstructured":"Haibel\u00a0H, Redeker\u00a0I, Zink\u00a0A, Callhoff\u00a0J, Marschall\u00a0U, Hoffmann\u00a0F, Sieper\u00a0J, Poddubnyy\u00a0D (2019) Gesundheitsversorgung und Krankheitslast bei Personen mit axialer Spondyloarthritis in Deutschland. Z Rheumatol 78(9):865\u2013874. https:\/\/doi.org\/10.1007\/s00393-019-0650-7","journal-title":"Z Rheumatol"},{"issue":"6","key":"1847_CR19","doi-asserted-by":"publisher","first-page":"564","DOI":"10.3899\/jrheum.180668","volume":"46","author":"A Luque Ramos","year":"2019","unstructured":"Luque Ramos\u00a0A, Redeker\u00a0I, Hoffmann\u00a0F, Callhoff\u00a0J, Zink\u00a0A, Albrecht\u00a0K (2019) Comorbidities in Patients with Rheumatoid Arthritis and Their Association with Patient-reported Outcomes: Results of Claims Data Linked to Questionnaire Survey. J\u00a0Rheumatol 46(6):564\u2013571. https:\/\/doi.org\/10.3899\/jrheum.180668","journal-title":"J Rheumatol"},{"issue":"12","key":"1847_CR20","doi-asserted-by":"publisher","first-page":"2059","DOI":"10.1007\/s00296-017-3791-5","volume":"37","author":"A Luque Ramos","year":"2017","unstructured":"Luque Ramos\u00a0A, Albrecht\u00a0K, Zink\u00a0A, Hoffmann\u00a0F (2017) Rheumatologic care of nursing home residents with rheumatoid arthritis: a comparison of the year before and after nursing home admission. Rheumatol Int 37(12):2059\u20132064. https:\/\/doi.org\/10.1007\/s00296-017-3791-5","journal-title":"Rheumatol Int"}],"container-title":["Zeitschrift f\u00fcr Rheumatologie"],"original-title":[],"language":"de","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00393-026-01847-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00393-026-01847-9","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00393-026-01847-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,9]],"date-time":"2026-09-09T08:53:56Z","timestamp":1788944036000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00393-026-01847-9"}},"subtitle":["Jahresbericht 2026 aus der Kerndokumentation der regionalen kooperativen Rheumazentren","Annual report 2026 from the National Database of the regional Collaborative Arthritis Centers"],"short-title":[],"issued":{"date-parts":[[2026,7,16]]},"references-count":20,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2026,9]]}},"alternative-id":["1847"],"URL":"https:\/\/doi.org\/10.1007\/s00393-026-01847-9","relation":{},"ISSN":["0340-1855","1435-1250"],"issn-type":[{"value":"0340-1855","type":"print"},{"value":"1435-1250","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,16]]},"assertion":[{"value":"13 May 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 June 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 July 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"J.\u00a0Callhoff: Referentenhonorare von Janssen, Pfizer, Idorsia. T.\u00a0Alexander: Honorare f\u00fcr Advisory Boards und\/oder Vortr\u00e4ge von AbbVie, Amgen, Astra Zeneca, GSK, Zenas BioPharma. M.\u00a0Aringer: Honorare f\u00fcr Advisory Boards und\/oder Vortr\u00e4ge von AbbVie, Astra Zeneca, BMS, Chugai, Galapagos, GSK, Lilly, MSD, Novartis, Roche, Sanofi und UCB. J.\u00a0Detert: Advisory Board- und Vortragshonorare von AbbVie, Amgen, BMS, Eli Lilly, Galapagos, Gilead, Janssen, Novartis, Pfizer, UCB. M.\u00a0Feuchtenberger: Honorare f\u00fcr Advisory Boards und\/oder Vortr\u00e4ge von AbbVie, Lilly, MSD, Novartis, Pfizer, Celltrion, UCB. J.\u00a0Henes: Vortragshonorare f\u00fcr Abbvie, Astra-Zeneca, Boehringer-Ingelheim, BMS, Janssen, Lilly, Novartis, Pfizer, Roche, SOBI, Otsuka, EUSA und UCB. K.\u00a0Karberg: Vortragshonorare von Abbvie, UCB, Novartis und der Rheumaakademie. U.\u00a0Kiltz: Vortrags\u2011\/Beratungshonorare von AbbVie, Alfasigma, Amgen, Biocad, Biogen, Chugai, Eli Lilly, Fresenius, Gilead, Gr\u00fcnenthal, GSK, Janssen, MSD, Novartis, Pfizer, Roche, Sanofi und UCB; Forschungsunterst\u00fctzung: Abbvie, GBA, Hexal, Novartis, Sanofi und UCB. B.\u00a0K\u00f6hler: Vortragshonorare von Abbvie, Lilly und Novartis, Beratungshonorare von Abbvie, Amgen, Lilly, Pfizer, UCB und Unterst\u00fctzung f\u00fcr Kongressreisen\/-teilnahme von UCB, Pfizer, Lilly und abbvie. U.\u00a0Schneider: Abbvie, AstraZeneca, Boehringer-Ingelheim, CSL-Vifor, GSK, Kyverna, Novartis, Roche, Sobi. S.\u00a0Sp\u00e4thling-Mestekemper: Vortrags\u2011\/Beraterhonorare von Abbvie, Astra Zeneca, BMS, Gilead, Gr\u00fcnenthal, GSK, Janssen, Lilly, MSD, Novartis, Pfizer, UCB. M.\u00a0Steinm\u00fcller: Vortrags\u2011\/Beratungshonorare von Abbvie, Amgen, Berlin Chemie, BMS, Galapagos, Gilead, GSK, Janssen, Lilly, Medac, MSD, Mylan, Novartis, Pfizer und ViiV. A.\u00a0Strangfeld: Referentenhonorare von AbbVie, Alfasigma, Biogen, Janssen, Lilly, Pfizer und Takeda. S. Zinke: Studien\/Vortragst\u00e4tigkeit\/Hospitationen\/Beratert\u00e4tigkeit\u00a0f\u00fcr AbbVie, Alfasigma, AstraZeneca, GSK, Johnson&Johnson, Lilly, Novartis, SanofiGenzyme und\u00a0UCB.\u00a0K.\u00a0Albrecht, K.\u00a0Thiele, T.\u00a0Eidner, J.G.\u00a0Richter und G.\u00a0Sch\u00e4fer geben an, dass kein Interessenkonflikt besteht.","order":1,"name":"Ethics","label":"Interessenkonflikt","group":{"name":"EthicsHeading","label":"Einhaltung ethischer Richtlinien"}},{"value":"Alle beschriebenen Untersuchungen am Menschen oder an menschlichem Gewebe wurden mit Zustimmung der zust\u00e4ndigen Ethikkommission, im Einklang mit nationalem Recht sowie gem\u00e4\u00df der Deklaration von Helsinki von 1975 (in der aktuellen, \u00fcberarbeiteten Fassung) durchgef\u00fchrt. Alle Patienten geben bei Teilnahme an der Kerndokumentation ihr schriftliches Einverst\u00e4ndnis. Die Ethikkommission der Charit\u00e9-Universit\u00e4tsmedizin Berlin hat die Studie genehmigt (EA1\/196\/06 und EA1\/093\/24).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Einhaltung ethischer Richtlinien"}}]}}